Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-beta-D-Digitoxosyl-Mithramycin SK (EC-8042) by Fernández Guizán, Azahara et al.
RESEARCH ARTICLE
Pleiotropic Anti-Angiogenic and
Anti-Oncogenic Activities of the Novel
Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-
Mithramycin SK (EC-8042)
Azahara Fernández-Guizán1, Alejandro López-Soto1,2, Andrea Acebes-Huerta1,
Leticia Huergo-Zapico1, Mónica Villa-Álvarez1, Luz-Elena Núñez3, Francisco Morís3,
Segundo Gonzalez1*
1 Department of Functional Biology, IUOPA, Universidad de Oviedo, Oviedo, Spain, 2 Department of
Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain, 3 EntreChem S.L., Campus El
Cristo, 33006-Oviedo, Spain
* segundog@uniovi.es
Abstract
Demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (DIG-MSK) is a recently isolated ana-
logue of mithramycin A (MTA) that showed differences with MTA in the DNA binding
strength and selectivity. These differences correlated with a better therapeutic index and
less toxicity in animal studies. Herein, we show that DIG-MSK displays a potent anti-tumor
activity against different types of cancer cell lines, ovarian tumor cells being particularly sen-
sitive to this drug. Of relevance, DIG-MSK exerts low toxicity on fibroblasts and peripheral
blood mononuclear cells, this toxicity being significantly lower than that of MTA. In correla-
tion with its antitumor activity, DIG-MSK strongly inhibited Sp1-mediated transcription and
endogenous Sp1mRNA expression, which correlated with the inhibition of the expression
of key Sp1-regulated genes involved in tumorigenesis, including VEGFA, BCL2L1 (Bcl-XL),
hTERT, BRCA2,MYC and SRC in several ovarian cells. Significantly, DIG-MSK was a
stronger inhibitor of VEGFA expression than MTA. Accordingly, DIG-MSK also exhibited
potent anti-angiogenic activity on microvascular endothelial cells. Likewise, it significantly
inhibited the gene expression of VEGFR1, VEGFR2, FGFR, PDGFB and PDGFRA and, addi-
tionally, it induced the expression of the anti-angiogenic factors angiostatin and tunstatin.
These effects correlated with a pro-apoptotic effect on proliferating microvascular endothe-
lial cells and the inhibition of the formation of endothelial capillary structures. Overall, the
pleiotropic activity of DIG-MSK in inhibiting key oncogenic and angiogenic pathways,
together with its low toxicity profile, highlight the therapeutic potential of this new drug.
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Introduction
Induction of angiogenesis is a hallmark of the tumorigenic process that plays a key role in
tumor progression and metastasis [1]. Cancer cells secrete pro-angiogenic factors that stimu-
late capillary growth into the tumor bed. Vascular endothelial growth factor (VEGF) is a crucial
angiogenic factor that comprises two structurally and functionally related proteins termed
VEGFA and VEGFB, being VEGFA the dominant angiogenic factor in most settings [2,3].
VEGF functions as a ligand for two tyrosine kinase receptors: vascular endothelial growth fac-
tor receptor 1 (VEGFR1) and 2 (VEGFR2), both expressed on the surface of endothelial cells
(ECs). Additionally, a redundant number of angiogenic factors, including angiopoietins, plate-
let-derived growth factor (PDGF) and fibroblast growth factor (FGF), collaborate with VEGF
in the angiogenic process [4].
Anti-angiogenic drugs, mainly targeting VEGF and PDGF, have been successfully intro-
duced in the anti-cancer therapy [5,6]. Bevacizumab, a humanized anti-VEFGA antibody, sig-
nificantly improved the prognosis of colorectal cancer patients [7]. Multiple inhibitors
targeting VEGFR2 and other angiogenic factors, such as sunitinib and sorafenib, displayed
promising effects on renal carcinoma patients [5,6]. However, many tumors sooner or later
become refractory or resistant to VEGF blockade. This resistance is frequently caused by the
activation of alternative angiogenic proteins, such as FGFs, due to preexisting multiple redun-
dant pro-angiogenic molecules and pathways [5,6,8].
Mithramycin A (MTA) is an aureolic acid-type polyketide antibiotic produced by various
species of Streptomyces [9]. MTA binds to GC-rich regions in DNA and interferes with the
action of several transcription factors; including Sp1. Toxic side effects of MTA have limited its
clinical use to the treatment of Paget’s disease and hypercalcemia [10]. Nevertheless, the inter-
est in MTA as an anti-cancer drug has been renewed in 2012, when two clinical trials
(NCT01610570 and NCT01624090) were launched at the National Cancer Institute to treat
Ewing sarcoma and non-small cell lung cancer. The expansion of mithramycin chemical diver-
sity through combinatorial biosynthesis and biocatalysis has yielded dozens of mithralogs [11].
A promising mithralog with improved therapeutic window, named DIG-MSK (demycarosyl-
3D-ß-D-digitoxosyl-mithramycin SK; EC-8042) has been reported (Fig 1). We showed that
DIG-MSK is as efficient as MTA in inhibiting Sp1 function, but it differs fromMTA in the
strength and selectivity of DNA binding [12]. Likewise, DIG-MSK is a stronger inhibitor of
endogenous SP3 gene expression and Sp3-driven transcription than MTA [12]. In vivo, the
mithralog EC-8042 exerts a potent antitumor activity against ovarian, colon, breast, melanoma,
non-small-cell lung and central nervous system cancers, but it is one order of magnitude less
toxic than MTA [13].
Sp1 regulates key angiogenic factors, including VEGF, FGF and FGF receptor (FGFR); and
the therapeutic inhibition of Sp1 by MTA directly correlated with potent anti-angiogenic
effects in vitro and in vivo [14–18]. Herein, we report that DIG-MSK has a pleiotropic anti-
tumor activity, targeting key oncogenic and angiogenic pathways, including those mediated by
VEGF, FGF or PDGF. The potent and pleiotropic biological activities exerted by DIG-MSK
and its better toxic profile highlight the potential relevance of this agent to treat cancer.
Materials and Methods
Mithralogs
MTA and DIG-MSK (EC-8042) were isolated from Streptomyces argillaceus, purification was
carried out by preparative HPLC and they were identified by HPLC-MS [13]. Their purity was
checked by HPLC (~97%). Stock solutions of the different analogues were prepared in DMSO
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Cell culture
A2780, OVCAR-3, IGROV-1 SK-OV-3, MCF-7, PANC-1, DLD1, HT-29 and 3T3 cells (all
from ATCC) were cultured in DMEM (Lonza). Medium was supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Sigma), 2 mM L-glutamine (Invitrogen), 1 mM pyruvate
Fig 1. Chemical formulae of mithramycin A (MTA) and demycarosyl-3D-b-D-digitoxosyl-mithramycin
SK (DIG-MSK).MTA differs from DIG-MSK in the side chain linked to C-3, and the absence of the methyl
group at C-3 on sugar E.
doi:10.1371/journal.pone.0140786.g001
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(Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma). HUVEC (ATCC) and
HMEC-1 cells (gently provided by Leadartis) were grown in MCDB-131 (Gibco BRL, Rock-
ville, MD) supplemented with 10% heat-inactivated FBS (Invitrogen), 0.01 mg/ml endothelial
cell growth supplement (Sigma Aldrich) and 1 ng/ml hydrocortisone. Peripheral blood mono-
nuclear cells (PBMCs) were purified from freshly isolated blood by Ficoll1-Paque (Sigma) gra-
dient centrifugation and cultured in RPMI-1640 (Lonza) supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 1 mM pyruvate, 100 U/ml penicillin and 100 μg/ml
streptomycin.
SRB assay
The effect of MTA or DIG-MSK on cell viability was determined by using the SRB-method, as
described elsewhere [19]. Cell viability was measured after 48 hours of treatment and IC50 val-
ues were calculated using the SRB assay carried out in triplicate.
VEGFR1 and VEGFR2 expression analysis
Cell surface protein expression of VEGFR1 and VEGFR2 was evaluated by flow cytometry by
using the following primary antibodies: anti-VEGFR1 (sc-271789, Santa Cruz Biotechnologies)
and anti-VEGFR2 (sc-504, Santa Cruz Biotechnologies). After washing, cells were stained with
a fluorescein isothiocyanate (FITC)-conjugated secondary antibody (AbD Serotec) and were
analyzed by flow cytometry (BD FACScanto, Becton Dickinson).
Apoptosis and cell cycle analyses
Cells were treated with 200 nMMTA or DIG-MSK and DMSO for 48 hours. Adherent and
detached (floating) cell populations were pooled together, and the percentage of cell death by
apoptosis and necrosis was determined by flow cytometry (BD FACScanto, Becton Dickinson)
after double staining with anti-annexin V antibody (Immunostep) and 7-AminoActinomycin
D (7-AAD) (Immunostep). Primary apoptosis was determined as the Annexin-V positive/
7-AAD negative cell population. Necrotic cells were characterized as Annexin-V negative/
7-AAD positive (primary necrotic cells) and Annexin-V positive/ 7-AAD positive (necrosis
arising from apoptotic cells or primary necrosis). Specific cell death was calculated using the
following formula: % specific cell death = (% death cell of sample–% death cells of negative
control)/(100 - % death cells of negative control) x 100.
The activity of caspases 3 and 9 was measured by using the Caspase 3 Colorimetric Kit (Life
Technologies) and the Caspase 9 Fluorimetric Kit (Invitrogen), following the manufacturer’s
recommendations.
For cell cycle analysis, cells were treated with MTA (200 nM) or DIG-MSK (200 nM) for
various periods of time; cells were harvested, fixed with 70% ethanol, stained with propidium
iodide (PI, Sigma) and analyzed by flow cytometry.
Migration assays
HUVEC and HMEC-1 cells were cultured until convergence and, then, cells were wounded by
scratching, rinsed with PBS, and incubated with DMSO, or several doses of MTA or DIG-MSK.
Wound closure was monitored over time by using an inverted microscopy (Motic AE2000)
and a compatible camera (Motican 1000, Motic). Images were captured at 0, 16, 24, 48 and 72
hours and analyzed with ImageJ software (NCBI). Experiments were made by triplicate and
cell migration was expressed as the percentage of distance migrated divided by the length of
the initial wound.
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Capillary-like Structure Formation Assay
HMEC-1 cells were incubated in 96 well plates treated with Matrigel, and treated with several
doses of MTA or DIG-MSK. After 48 hours, capillary-like structures formation was captured
and processed with Angiodraw Software. The angiogenic index (AI) was calculated as the num-
ber of branch points in a field. The experiments were made by triplicate and four different
fields were counted for each experiment.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was isolated from cells treated with DMSO, MTA (200 nM), or DIG-MSK (200
nM) for 8 hours using the High Pure RNA Isolating kit (Roche). cDNA was obtained using
High Capacity cDNA Reverse Transcription Kit (Invitrogen). Quantitative Real Time PCR
(qRT-PCR) was performed in triplicate by using HT7900 RT-PCR and SYBR Green PCRMas-
ter Mix (Applied Biosystems). The sequences of the oligos used for real-time PCR are shown in
Table 1. The thermal profile was 95°C for 3 minutes, followed by 40 cycles of 95°C for 20 sec-
onds; annealing temperature (specific for each gene, see Table 1) for 30 seconds and 70°C for
30 seconds. Relative expression values of the different genes were calculated from the threshold
cycle (Ct) following the 2−ΔΔCT method and using GAPDH as internal housekeeping control
gene for normalization.
Table 1. qRT-PCR primers used and thermal profiles.
GENE FOWARD PRIMER REVERSE PRIMER T°
C-MYC 5´-GGTCTCCCCTACCCTCTCAACGA-3´ 5´-GGCAGCAGGATAGTCCTTCCGAGT-3´ 55°C
C-SRC 5´-GTCTGACTTCGACAACGCCAAG-3´ 5´-CCCCTTGAGAAAGTCCAGCAA-3´ 55°C
TERT 5´-TGAACTTGCGGAAGACAGTG-3´ 5´-GGGTTCTTCCAAACTTGCTG-3´ 60°C
BCL-XL 5´-GAAGGGACTGAATCGGAGATGGAGAC-3´ 5´-AGAGTGGATGGTCAGTGTCTGGTCAT-3´ 55°C
BRCA2 5´-CGTACACTGCTCAAATCATTC-3´ 5´-GACTAACAGGTGGAGGTAAAG-3´ 60°C
MICA 5´-CACCTGCTACATGGAACACAGC-3´ 5´-TATGGAAAGTCTGTCCGTTGACTCT-3´ 60°C
P21 5´-GGAAGACCATGTGGACCTGT-3´ 5´-AAGATGTAGAGCGGGCCTTT-3´ 60°C
FGF 5´-CAGCTGTACAAGAACAGAGGCTTTC-3´ 5´-AAATGGGTCCATGCTGTCGGTCTCC-3´ 60°C
FGFR 5´-CATCCGCTGGCTTAAGGATGGAC-3´ 5´-ATCACGAGACTCCAGTGCTGATG-3´ 60°C
PDGFA 5´- CCCCTGCCCATTCGGAGGAAGAG-3´ 5´-TTGGCCACCTTGACGCTGCGGTG-3´ 62°C
PDGFB 5´-GATCCGCTCCTTTGATGATC-3´ 5´-GTCTCACACTTGCATGCCAG-3´ 60°C
PDGFRA 5´-ATCAATCAGCCCAGATGGAC-3´ 5´-TTCACGGGCAGAAAGGTACT-3´ 60°C
PDGFRB 5´-AATGTCTCCAGCACCTTCGT-3´ 5´-AGCGGATGTGGTAAGGCATA-3´ 58°C
EGF 5´-TGCCAACTGGGGGTGCACAG-3´ 5´-CTGCCCGTGGCCAGCGTGGC-3´ 60°C
VEGFA 5´-AGGAGGAGGGCAGAATCATCA-3´ 5´-CAGGGATTTTCTTGTCTTG-3´ 62°C
VEGFB 5´-AGCCAGTGTGAATGCAGA-3´ 5´-ATAGCCTCTGAGGCAAGT-3´ 62°C
VEGFC 5´-AGGCCACGGCTTATGCAA-3´ 5´-TAGACATGCATCGGCAGGAA-3´ 62°C
VEGFD 5´-CATCTCAGTCCACAT TGG-3´ 5´-GGCAAGCACTTACAACCT-3´ 62°C
VEGFR1 5´-AAAAACAACCACAAAATACAACAA-3´ 5´-TCTTAATGCCAAATGCTGATGCTT-3´ 50°C
VEGFR2 5´-ACGTCTGGTCTTTTGGTGTTTTGC-3´ 5´-ATACTGACTGATTCCTGCTGTGTT-3´ 50°C
VEGFR3 5´-CCTGAAGAAGATCGCTGTTC-3´ 5´-GAGAGCTGGTTCCTGGAGAT-3´ 65°C
HIF1A 5´-TGCTTGGTGCTGATTTGTGA-3´ 5´-GGTCAGATGATCAGAGTCCA-3´ 68°C
ENDOSTATIN 5´-ATGCTGACATTCACCTGCC-3´ 5´-ATGAAGTCAGCACCTGCTGG-3´ 60°C
ANGIOSTATIN 5´-AATTCCATGTGCAAGACTGGGAATGGAA-3´ 5´-TTGAATTCTTAACAGGACGGTATCTTACA-3´ 60°C
TSP1 5´-CCTCAGGAACAAAGGCTGCTC-3´ 5´-GCCAATGTAGTTAGTGCGGATG-3´ 60°C
TUMSTATIN 5´-TTAAAGGGAAATCCTGGTGAC-3´ 5´-GTTCTGGTTTCTTTGATTTCG-3´ 60°C
GAPDH 5´-CGGAGTCAACGGATTTGGTC-3´ 5´-ATCATATTGGAACATGTAAACCATGTAG-3´ 50–62°C
doi:10.1371/journal.pone.0140786.t001
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ELISA measurements of secreted VEGF in culture supernatants
A2780, OVCAR-3 and IGROV-1 cells were cultured in 6 well plates (1x106 cells/well) and
treated with MTA (200 nM), DIG-MSK (200 nM) or DMSO for 72 hours. Supernatants were
collected and VEGF level was measured by quantitative VEGF enzyme-linked immunosorbent
assay (ELISA) (Sigma Aldrich), according to the manufacturer's instructions.
Statistical analysis
Continuous variables were compared with Mann-Whitney U test. The p values<0.05 were
considered statistically significant.
Results
Effect of DIG-MSK on the toxicity and the cell cycle of cancer cell lines
and mononuclear blood cells
The effect of MTA and DIG-MSK on the viability of a panel of cell lines was analyzed by determin-
ing the drug concentrations required for inhibiting cell viability by 50% (IC50) [19]. MTA and
DIG-MSK strongly reduced the viability of most of the cell lines analyzed at low nanomolar doses
(Table 2). Lower concentrations of DIG-MSK thanMTA were needed to obtain equitoxic effects
on A2780 cells (2.84 nM vs. 13.75 nM; p<0.01) IGROV-1 cells (7.5 nM vs. 136 nM; p<0.001) and
MCF-7 cells (17.26 nM vs. 99.36 nM; p<0.001). Nevertheless, MTA was more toxic than
DIG-MSK on PANC-1 cells (Table 2). Of note, both drugs were particularly efficient on ovarian
cells, in which low nanomolar doses successfully inhibited cell viability. Conversely, the toxicity of
these analogues in embryo fibroblasts 3T3 was significantly lower than in cancer cell lines.
The toxic effect of these drugs on the ovarian cells was further analyzed by measuring apo-
ptosis (Fig 2A and 2B). Ovarian cells were treated with 200 nMMTA or DIG-MSK and cell
death was analyzed by annexin V staining. A strong cytotoxic effect was observed with both
analogues in the three cell lines analyzed, causing cell death by both apoptosis and necrosis
(ranging from 40% to 60%). Of note, the induction of apoptosis in PBMCs obtained from 6
healthy donors was very low (Fig 2B), causing DIG-MSK significantly lower toxicity than MTA
(2% vs. 12%; p<0.001). To extend these observations, caspase 3 and caspase 9 activities were
analyzed. Both drugs induced a significant increase in caspase 3 and 9 activities in ovarian cells
Table 2. Cytotoxic effect (IC50) of MTA and DIG-MSK against cancer cell lines and endothelial cell lines.
CELL LINE Cellular type MTA DIG-MSK P
A2780 Ovarian cancer 13.75 nM 2.84 nM <0.01
OVCAR-3 Ovarian cancer 3 nM 6.75 nM Ns
IGROV-1 Ovarian cancer 136 nM 7.5 nM <0.001
SK-OV-3 Ovarian cancer 10.50 nM 16.23 nM Ns
MCF-7 Brest cancer 99.36 nM 17.26 nM <0.001
PANC-1 Pancreatic cancer 33.83 nM 434.7 nM <0.001
DLD1 Colorectal cancer 209.9 nM 180 nM Ns
HT-29 Colorectal cancer 1.2 uM 2.56 nM Ns
HMEC-1 Umbilical vein endothelial cell 7 nM 8 nM Ns
HUVEC Umbilical vein endothelial cell 39.87 nM 47.15 nM Ns
3T3 Mouse embryo Fibroblast 2.56 μM 2.19 μM Ns
Ns: Non signiﬁcant
doi:10.1371/journal.pone.0140786.t002
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(Fig 2C and 2D). In agreement with the cell death, both MTA and DIG-MSK had a signifi-
cantly lower cytotoxic effect on healthy PBMCs than in ovarian cells, although the caspase 3
activity induced by DIG-MSK was significantly lower than MTA (p<0.01).
Fig 2. Pro-apoptotic activity of MTA and DIG-MSK in ovarian andmononuclear blood cells. a) Ovarian cells and PBMCswere treated with MTA (200
nM), DIG-MSK (200 nM) or DMSO and cell death was analyzed by flow cytometry by staining the treated cells with Annexin-V-FITC and 7-AAD. b) The bars
represent the mean ± SEM of the specific cell death of at least three independent experiments. PBMCs were obtained from six unrelated donors. c and d)
Analysis of caspase-3 and -9 activities in ovarian cells and PBMCs treated with 200 nMMTA or DIG-MSK compared to vehicle (DMSO) treated cells. The bars
represent the mean ± SEM of the units (U) of caspase activity obtained from at least three independent experiments (*p<0.05; **p<0.01, Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g002
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Fig 3. Cell cycle distribution in ovarian cancer cells treated with MTA and DIG-MSK. a) Ovarian tumor
cells were treated with MTA (200 nM), DIG-MSK (200 nM) or DMSO, and the cell cycle distribution was
analyzed by propidium iodide (PI) staining and flow cytometry analysis. Representative histograms of
OVCAR-3 cells are shown. b) The bars represent the mean ± SEM of the percentage of cells in the different
phases of the cell cycle in IGROV-1, A2780 and OVCAR-3 ovarian carcinoma cells. The results are obtained
from at least three independent experiments (drug vs. DMSO; *p<0.05; **p<0.01, Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g003
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Next, we analyzed the effect of MTA and DIG-MSK on the proliferation of ovarian tumor
cells by analyzing the cell cycle distribution. As shown in Fig 3, both analogues halted the cell
cycle and induced a G1 arrest in IGROV-1 and OVCAR-3 cells, whereas no such effect was
observed in A2780 cells.
DIG-MSK inhibits the expression of Sp1-target genes in ovarian cancer
cells
To get further insight into the signaling pathways underlying the activity of MTA and
DIG-MSK, the effect of these compounds on the expression of a transfected luciferase reporter
vector containing several Sp1-response elements was determined. Both drugs were potent
inhibitors of Sp1-mediated transcriptional activity in ovarian cells (Fig 4A). In agreement, they
were also potent inhibitors of endogenous Sp1 expression and the transcription of eight
Sp1-target genes involved in key aspects of the ovarian tumorigenesis as determined by
qRT-PCR (Fig 4B and 4C). MTA and DIG-MSK significantly down-regulated the transcript
levels of VEGFA, BCL2L1 (Bcl-XL), hTERT, BRCA2,MYC and SRC genes. DIG-MSK showed,
in general, a similar or stronger inhibitory effect than MTA on the transcription of such
Sp1-regulated genes. Particularly, DIG-MSK was more efficient than MTA in inhibiting
VEGFA gene expression in A2780 cells (1.3-fold), OVCAR-3 cells (2.8-fold, p<0.05) and
IGROV-1 (3.2-fold, p<0.001) cells (Fig 4C). However, a stronger induction of P21 andMICA
expression was observed upon treatment with MTA, the latter being a gene involved in the acti-
vation of the anti-tumor immune response [20].
DIG-MSK exerts a pro-apoptotic effect and suppresses tube formation
by microvascular endothelial cells
To further analyze the anti-angiogenic properties of DIG-MSK, its effect on microvascular
endothelial cells (ECs) was analyzed. No significant effect was observed on cell cycle progres-
sion in HUVEC or HMEC-1 cells (Fig 5A). Likewise, no EC migration was not significantly
affected by DIG-MSK, as determined by the wound/scratch-healing assay (not shown). How-
ever, DIG-MSK treatment induced significantly lower levels of cell death in HUVEC cells than
MTA, with no marked differences observed in HMEC-1 cells (Fig 5B).
Next, the formation of new blood vessel was analyzed by conducting the endothelial tube
formation assay in which Matrigel was used as a substrate. The integrity of the capillary-like
structure formed by HMEC-1 cells was significantly inhibited by DIG-MSK in a dose-depen-
dent manner, and this effect was observed at non-cytotoxic doses (Fig 6 and S1 Fig). However,
MTA was only able to inhibit capillary-like formation at high doses, which was associated with
a high toxicity in HMEC-1 cells.
MTA and DIG-MSKmodulate the expression of angiogenic genes in
human microvascular endothelial cells
To gain further insight into the mechanism underpinning the suppression of capillary forma-
tion by DIG-MSK, the impact of this drug on the transcription of key angiogenic genes
(VEGFA, VEGFB, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, FGF, FGFR, PDGFA,
PDGFB, PDGFRA, PDGFRB, EGF and HIF1A) in ECs was analyzed by qRT-PCR. As shown in
Fig 7A, a significant reduction in VEGFR1 and VEGFR2 gene expression in HUVEC cells
(ranging from 40 to 50% of inhibition). A down-regulation of VEGFR2, FGFR and PDGFRA
gene expression was observed with both analogues in HMEC-1 cells. DIG-MSK also inhibited
VEGFR1 and PDGFB expression in these cells (Fig 7A and 7B). Contrarily, MTA significantly
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Fig 4. DIG-MSK regulates the expression of SP1 and key oncogenic genes in ovarian tumor cells. (a) Relative changes in luciferase activity of a
transfected Sp1-reported vector in the presence of 200 nMMTA or DIG-MSK compared to untreated ovarian cancer cells. qRT-PCR analysis of the
expression of SP1 gene and several key Sp1-regulated oncogenic genes in ovarian cancer cells treated or untreated with 200 nMMTA or DIG-MSK. Data
represent the mean ± SEM of Ct values obtained from at least three independent experiments made by duplicate. The relative mRNA expression was
obtained by comparison of the expression profiles of untreated cells (DMSO) versus treated ones (*p<0.05; **p<0.01, Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g004
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up-regulated the angiogenic factor PDGFA in HUVEC cells. Similarly, their effect on the tran-
script levels of key anti-angiogenic genes encoding angiostatin, tunstatin, endostatin and
thrombospondin-1 was analyzed (Fig 8). Angiostatin gene expression was up-regulated by both
analogues and tunstatin was induced by DIG-MSK in HUVEC cells. Conversely, a reduction of
endostatin expression was observed in HUVEC cells treated with both drugs.
Effect of MTA and DIG-MSK on the secretion of VEGF and the surface
expression of VEGFR1 and VEGFR2
Given the strong inhibition of VEGF gene expression in ovarian cancer cells, and the reduction
of the mRNA expression of VEGF receptors observed in ECs upon exposure to MTA and
DIG-MSK, we next studied the modulation of these key regulators of the angiogenic process at
Fig 5. Cell cycle distribution and pro-apoptotic effect on microvascular endothelial cells upon exposure to MTA and DIG-MSK. a) HUVEC and
HMEC-1 cells treated with MTA (200 nM) or DIG-MSK (200 nM) or DMSOwere stained with propidium iodide (PI) and the cell cycle distribution was analyzed
by flow cytometry. A representative cytometric profile of HUVEC cells is shown. b) Cell death was analyzed by flow cytometry in ECs (HUVEC and HMEC-1
cells) treated with 200 nMMTA, DIG-MSK or in untreated cells after staining them with Annexin-V and 7-AAD. The bars represent the mean ± SEM of the
specific cell death. At least three independent experiments were analyzed (*p<0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g005
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protein level under these conditions. ELISA analyses demonstrated that both drugs strongly
inhibited the secretion of VEGFA in ovarian tumor cells (A2780 cells; MTA: 2.39-fold,
DIG-MSK: 2.55-fold, p<0.05; OVCAR-3 cells; MTA: 2.40-fold, DIG-MSK: 3.44-fold, p<0.05)
(Fig 9A). Further, both drugs completely inhibited the production of VEGFA in IGROV-1 cells
(15.4-fold MTA, 19.63-fold DIG-MSK, p<0.05). Of note, in OVCAR-3 cells, DIG-MSK was
significantly more efficient than MTA in inhibiting the secretion of VEGFA (1.45-fold,
p<0.05). Likewise, flow cytometry analyses also showed that surface expression of VEGFR1
and VEGFR2 was significantly down-regulated by MTA and DIG-MSK in HUVEC and
HMEC-1 cells (p<0.01) (Fig 9B).
Fig 6. Effect of MTA and DIG-MSK on tube formation by humanmicrovascular endothelial cells. a) HMEC-1 cells were seeded onto Matrigel-coated
wells and incubated with DMSO or various concentrations of MTA and DIG-MSK for 48 hours. Capillary-like structures formation was captured and
processed with Angiodraw Software. Angiogenic index was calculated as the number of branch points in a field. The bars represent the mean ± SEM of the
angiogenic index of four independent experiments (*p<0.05; Mann-Whitney U test). b) Representative appearance of HMEC-1 tube formation. Untreated
control cells and cells treated with MTA and DIG-MSK are presented.
doi:10.1371/journal.pone.0140786.g006
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Fig 7. MSK and DIG-MSKmodulate the expression of key angiogenic genes in ovarian carcinoma
cells. a) qRT-PCR analysis of the expression of several key angiogenic genes in the presence of 200 nM
MTA or DIG-MSK compared with untreated ECs. Data represent the mean ± SEM of Ct values obtained from
at least three qRT-PCR independent experiments made by duplicate. The relative mRNA expression was
obtained by comparison of the expression profiles of untreated cells (DMSO) versus treated ones (*p<0.05;
**p<0.01; Mann-Whitney U test). b) Venn diagrams representing genes down-regulated by treatment with
MSK or DIG-MSK (p<0.05). Numbers inside the intersections correspond to genes repressed by both
treatments.
doi:10.1371/journal.pone.0140786.g007
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Overall, our results show that DIG-MSK has a pleiotropic anti-angiogenic effect by up-regu-
lating the expression of key angiogenic genes as well as repressing the transcription of key anti-
angiogenic genes, indicating that this new drug may be useful for anti-cancer therapies that tar-
get angiogenic pathways.
Discussion
MTA is a DNA-binding drug that shows preference for G/C-rich DNA sequences, and, there-
fore, a significant part of the anti-tumor activity of MTA is thought to be mediated by the
blockade of the binding of transcription factors such as Sp1 [21]. Sp1 expression and activity
Fig 8. Analysis of the expression of key anti-angiogenic genes in ECs treated with MTA or DIG-MSK. qRT-PCR analysis of the expression of several
key anti-angiogenic genes in the presence of 200 nMMTA or DIG-MSK compared to untreated ECs. Data represent the mean ± SEM of Ct values obtained
from at least three qRT-PCR independent experiments made by duplicate in HUVEC (a) or HMEC-1 (b) endothelial cells. The relative mRNA expression was
obtained by comparison of the expression profiles of untreated cells (DMSO) versus treated ones (*p<0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g008
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are up-regulated in many cancers, correlating with advanced stage and poor prognosis [22–
26]. Accordingly, Sp1 inhibition may decrease tumor formation, growth and metastasis
Fig 9. Effect of MTA and DIG-MSK on the secretion of VEGF and the surface expression of VEGFR1
and VEGFR2. a) Soluble VEGF levels were measured by ELISA in supernatants of ovarian carcinoma cells
(A2780, OVCAR-3 and IGROV-1) treated with 200 nMMTA or DIG-MSK compared with untreated cells. b)
The surface expression of VEGFR1 and VEGFR2 was analyzed by flow cytometry in ECs treated with 200
nMMTA or DIG-MSK relative to DMSO treated cells. Data represent the mean ± SEM of levels obtained from
at least three independent experiments. (*p<0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0140786.g009
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[14,27,28], representing an attractive target, despite being considered undruggable by conven-
tional drug discovery approaches [29].
DIG-MSK is a novel analogue of MTA that shares the general features of other mithralogs,
such as the preference for binding to G/C-rich DNA sequences and inhibition of Sp1-driven
transcription [21]. Nevertheless, DIG-MSK has significant differences in the strength and spec-
ificity of DNA binding [12]. Thus, DIG-MSK is a stronger inhibitor of the expression of Sp3
and Sp3-driven transcription than MTA. In spite of the fact that Sp1 and Sp3 recognize the
same DNA element with similar affinity, these two transcription factors possess different func-
tions, and the relative level of both proteins differentially regulates the expression of several
genes [22,30, 31,32]. Overall, these differences between MTA and DIG-MSK point that differ-
ent therapeutic activity and toxicity between both analogues may exist. In fact, initial studies
reported that DIG-MSK has an improved therapeutic index compared to the parental MTA,
since it is one order of magnitude less toxic than MTA in vivo [13]. In agreement, in our study
we report that DIG-MSK displays low toxicity in primary cells. The toxicity of MTA and
DIG-MSK was low in mouse embryo fibroblasts and mononuclear blood cells obtained from
healthy donors, and, in these cells, DIG-MSK showed significantly lower toxicity than MTA.
These results are in agreement with in vivo studies were DIG-MSK has been well tolerated and
no evidence of toxicity or cell death was observed in ovarian cells and other tissues [13].
Noteworthy, DIG-MSK retains a potent anti-tumor activity against cells obtained from dif-
ferent types of cancers, but ovarian cells were particularly sensitive to this drug. Similar to the
parental MTA, DIG-MSK potently inhibited Sp1-mediated transcription in these ovarian
tumor cells, and, given that the Sp1 gene is autoregulated in a positive feedback, DIG-MSK was
also a potent inhibitor of endogenous Sp1 expression. In correlation, DIG-MSK inhibited
Sp1-regulated genes involved in the expression of key oncogenic processes, such as DNA repair
(BRCA2), cell proliferation (MYC, SRC), telomere maintenance (hTERT) and cell survival
(BCL-XL). Notably, p21WAF1/CDKN1A, which is involved in halting cells at G1 and G2/M
phases, was induced in OVCAR-3 and IGROV-1, which correlated with a halt of the cell cycle
and G1 arrest.
Of note, one of the genes strongly inhibited by DIG-MSK was VEGFA, which is a well-
known Sp1-regulated gene in cancer [33,34]. In fact, it has been reported that MTA is a strong
inhibitor of VEGF and it shows potent anti-angiogenic effects [14–18]. Nevertheless, we
observed that DIG-MSK was more efficient than MTA in inhibiting key angiogenic genes.
Thus, DIG-MSK was a strong inhibitor of VEGF pathway; but, contrasting with other anti-
angiogenic drugs, DIG-MSK showed a dual effect inhibiting both VEGFA expression in cancer
cells and VEGFR1 and VEGFR2 expression in ECs. Further, it also reduces the expression of
other key angiogenic receptors, such as FGFR, PDGFRA and PDGFRB. Additionally, it up-reg-
ulates the expression of the anti-angiogenic genes encoding for angiostatin and tunstatin. The
up-regulation of anti-angiogenic factors by MTA treatment has been previously described and
it has been shown to exert anti-myeloma effect in vivo [17]. Conversely, MTA treatment
increased PDGFRAmRNA expression and both drugs inhibited the expression of endostatin in
HUVEC cells. However, these effects are cell-specific and could be linked to the specific charac-
teristics of the cell line or with the transformation mechanisms of these cells. Further studies
are needed to elucidate the role of DIG-MSK in the regulation of these genes in ECs. Neverthe-
less, the final effect of DIG-MSK treatment was a pro-apoptotic effect on proliferating micro-
vascular ECs and the inhibition of the formation of capillary structures at non-toxic doses,
which may be due to the effect of these angiogenic factors on the formation and stabilization of
new blood vessels. Of note, MTA has a more limited effect on the inhibition of angiogenic fac-
tors and it was unable to inhibit the formation of capillary-like structures at non-toxic
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concentrations, suggesting that DIG-MSK has improved anti-angiogenic properties compared
with the parental MTA.
Several anti-angiogenic drugs, mainly targeting VEGF and PDGF, have been successfully
introduced in the anti-cancer therapy [5,6]. The majority of these drugs are highly specific and
they are associated with low toxicity. However, many tumors become sooner or later refractory
or resistant to VEGF blockade. Compensation by other angiogenic factors, such as FGF and
angiopoietins, is a major factor that contributes to tumor resistance to VEGF blockade [35–
37]. Contrasting the majority of drugs against angiogenesis, DIG-MSK shows pleiotropic
effects on DNA targets that affect a wide range of Sp1-regulated genes. This array of anti-angio-
genic and anti-oncogenic activities has important advantages and disadvantages. On one hand,
they may limit the development of drug resistance. On the other hand, this multi-target activity
may be associated with elevated toxicity, which may limit its therapeutic use. Notably, among
many derivatives of MTA, DIG-MSK has been selected because it has showed a lower toxic
profile than MTA, which highlights the potential of this drug as an efficient and safer anti-can-
cer agent.
Supporting Information
S1 Fig. Original and processed images of HMEC-1 tube formation using different concen-
trations of MTA and DIG-MSK.
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